Announcements Trials
Browse Landscape

Status

Recruiting 10Unknown 5Not yet recruiting 5Completed 4Active not recruiting 3Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Hyperlipidemias 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 7Educational Status 7Cisplatin 7Standard of Care 6Interviews as Topic 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Carboplatin 5Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Drug Therapy 4lenvatinib 3camrelizumab 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Gemcitabine 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Dexamethasone 3Cytarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × OTHER × lorlatinib × Clear all
NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Peking University Third Hospital

Enrolling by invitation
167 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡